Pr Philippe Moreau
- Specialty
- Hematologist, multiple myeloma expert
- Hospital
- Centre Hospitalier Universitaire de Nantes
- Latest articles
-
- Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05). (Oct 5, 2026)
- Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study. (Oct 1, 2026)
- Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study. (Aug 30, 2026)
- Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. (Aug 24, 2026)
- Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results. (Aug 17, 2026)